1Jemal A, Thomas A, Murray T, et al.Cancer statistics, 2002. CA Cancer J Clin,2002, 52 (1):23-47.
2Jemal A, Thomas A, Murray T, et al.Cancer statistics, 2002. CA Cancer J Clin, 2002, 52(2):119.
3Jemal A, Thomas A, Murray T, et al.Cancer statistics, 2002.CA Cancer J Clin,2002,52(3):181-182.
4Sekido Y, Fong KM, Minna JD.Progress in understanding the molecular pathogenesis of human lung cancer, Biochim Biophys Acta, 1998,1378(1):F21-F59.
5Blot WJ, McLaughlin JK. Passive smoking and lung cancer risk: what is the storynow? J Natl Cancer Inst,1998,90(19):1416-1417.
6Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res, 1998,8(12):1229-1231.
7Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res, Genome Res,1999,9(2) : 210.
8Holliday R, Grigg GW. DNA methylationand mutation. Mutat Res, 1993,285 (1) :61-67.
9Nickerson DA, Taylor SL, Weiss KM, et al. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene.Nat Genet,1998,19(3) : 233-240.
1Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase,cytochrome P450, glutat hione- S - transferase, and epoxide hydrolase enzymes., relevance to xenobiotic metabolism and toxicity[J].Crit Rev Toxicol, 1999,29(1):59-124.
2Hayashi SI,Watanabe J,Nakachi K,et al. Genetic linkage of lung cancer- associated Msopl polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene [J]. J Biochem,1991,110,407-411.
3Nakachi K,Hayashi SI,Kawajiri K,et al. Associated of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation[J]. Carcinogenesis,1995,16(9) : 2209-2213.
4Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci, 2000,910:121-137.
5Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol,1999,19:1092-1100.
6Pierce LM, Sivaraman L, Chang W, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prey, 2000,9: 1199-1204.
7Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomatkers Prev, 2000, 9: 1037-1042.
8Peixoto Guimaraes D, Hsin Lu S, Snijders P, et al.Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett, 2001,162:231-235.
9Lee JM, Lee YC, Yang SY, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esoohagus. Int J Cancer, 2000,89:458-464.
10Storey A, Thomas M, Kalita A, et al. Role of a p53 polymerphism in the development of human papillomavirus-associated cancer. Nature,1998,393 : 229-234.
1FILMUS J. Glypicans in growth control and cancer[ J ]. Glycobiology, 2001,11(3) :I9R-23R.
2WANG Y, BRODERICK P, MATAKIDOU A, et al. Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 ( CHRNA5-CHRNA3 ) variation and lung cancer risk in never-smokers [ J ]. Carcinogenesis, 2010,31 (2) :234-248.
3GABRIELSON E. Worldwide trends in lung cancer pathology [ J ]. Respirology,2006,11 : 533-538.
4GAO Y, GOLDSTEIN A M, CONSONNI D, et al. Family history of cancer and nonmalignantlung diseases as risk factors for lung cancer [ J]. Int J Cancer,2009,125 : 146-152.
5LI X, HEMMINKI K. Inherited predisposition to early onset lung cancer according to histological type [ J]. Int J Cancer, 2004,112: 451-457.
6THORGEIRSSON T E, GELLER F, SULEM P, et ai. A variant associated with nicotinedependence, lung cancer and peripheral arterial disease[ J]. Nature ,2008,452:638-642.
7RAFNAR T,SULEM P,STACEY S N,et al. Sequence variants at the TERTCLPTM1L locus associate with many cancer types [ J ]. Nat Genet,2009,41:221-227.
8WU C,HU Z,YU D,et al. Genetic variants on chromosome i5q25 associated with lung cancer risk in Chinese populations [ J ]. Cancer Res,2009,69(12) :5065-5072.
9ZHANG M ,HU L,SHEN H,et al, Candidate variants at 6p21.33 and 6p22. 1 and risk of non-small cell lung cancer in a Chinese population [ J ]. Int J Mol Epidemiol Genet,2010,1 ( 1 ) : 11-18.
10MANOLIO T A, COLLINS F S. The HapMap and genome-wide association studies in diagnosis and therapy [ J ]. Annu Rev Med, 2009,60:443-456.
